{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-001784","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2024-01-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.027630+00:00","generated_at":"2026-06-06T20:58:16.680474+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sangamo Therapeutics eliminates 2023 executive bonuses, adopts retention program amid capital raise","bullets":["Board determined not to award 2023 annual cash bonus to CEO Sandy Macrae or CFO Prathyusha Duraibabu.","Retention program approved for US/UK employees; CEO eligible for up to $429,820, CFO up to $193,584.","Retention payments conditioned on achieving capital-raising milestones by end of 2024 or change of control.","Executives must remain employed through payment date; program highlights company's cash needs."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-001784","json":"https://secwatch.observer/filing/0001628280-24-001784.json","markdown":"https://secwatch.observer/filing/0001628280-24-001784.md","text":"https://secwatch.observer/filing/0001628280-24-001784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828024001784/0001628280-24-001784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828024001784/sgmo-20240119.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T20:58:16.680474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}